The Efficacy of Cationic Amphiphilic Antihistamines on Outcomes of Patients with Pancreatic Ductal Adenocarcinoma

被引:0
|
作者
Chiang, Cho-Han [1 ]
Chiang, Cho-Hung [2 ]
Hsia, Yuan Ping [3 ]
Chen, Brian Shiian [4 ]
Jaroenlapnopparat, Aunchalee [1 ]
Chiang, Cho-Hsien [5 ,6 ]
Peng, Cheng-Ming [4 ,7 ]
机构
[1] Harvard Med Sch, Mt Auburn Hosp, Dept Med, 330 Mt Auburn St, Cambridge, MA 02138 USA
[2] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[3] Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Family Med, New Taipei City, Taiwan
[4] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
[5] London Sch Hyg & Trop Med, London, England
[6] Natl Taiwan Univ Hosp, Dept Environm & Occupat Med, Taipei, Taiwan
[7] Chung Shan Med Univ Hosp, Da Vinci Minimally Invas Surg Ctr, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan
关键词
Cationic amphiphiphilic antihistamines; Pancreatic adenocarcinoma; Cohort study;
D O I
10.1007/s12029-023-00969-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Cationic amphiphilic H1-antihistamines have demonstrated antitumor effects in preclinical studies. We conducted a retrospective cohort study to investigate their impact on patients with pancreatic adenocarcinoma (PDAC). Methods We performed a matched cohort study involving PDAC patients from two tertiary centers in Taiwan using criteria including age, sex, and cancer stage. The primary outcome was overall survival (OS), and the secondary outcomes were progression-free survival (PFS) and objective response rates (ORR). Results We matched 28 cationic amphiphilic antihistamine users with 56 non-cationic amphiphilic antihistamine users. Cationic amphiphilic antihistamine users showed significantly longer OS (median 16.4 [IQR, 2.8 - 89.0] vs.5.8 [IQR, 2.0 - 9.8] months; p<0.001) and PFS (median 12.2 [IQR, 2.2 - 83.3] vs. 5.2 [IQR, 1.7 - 8.4] months; p=0.002) compared to non-users. In the Cox proportional hazard models, the use of cationic amphiphilic antihistamines was associated with approximately 60% lower risk of all-cause mortality and disease progression. Additionally, cationic amphiphilic antihistamine users exhibited a significantly greater ORR than non-users (39% vs. 7%, p=0.004). Conclusion Our study suggests that cationic amphiphilic antihistamines are associated with improved survival outcomes in PDAC patients.
引用
收藏
页码:175 / 177
页数:3
相关论文
共 50 条
  • [21] Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma
    Mori, Shozo
    Aoki, Taku
    Sakuraoka, Yuhki
    Shimizu, Takayuki
    Yamaguchi, Takamune
    Park, Kyung-Hwa
    Matsumoto, Takatsugu
    Shiraki, Takayuki
    Iso, Yukihiro
    Kubota, Keiichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (01) : 109 - 120
  • [22] Pancreatic ductal adenocarcinoma
    Gallmeier, E.
    Gress, T. M.
    GASTROENTEROLOGE, 2019, 14 (02): : 131 - 148
  • [23] Oncologic Outcomes of Cytoreductive Surgery and Hipec for Highly Selected Patients With Pancreatic Ductal Adenocarcinoma
    Gudmundsdottir, Hallbera
    Yonkus, Jennifer
    Thiels, Cornelius A.
    Warner, Susanne
    Cleary, Sean
    Kendrick, Michael
    Truty, Mark J.
    Grotz, Travis E.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S42 - S43
  • [24] Evolution of Outcomes of Patients With Pancreatic Ductal Adenocarcinoma Undergoing Pancreatoduodenectomy Following Preoperative Therapy
    Cloyd, Jordan M.
    Katz, Matthew H.
    Fleming, Jason B.
    Wolff, Robert A.
    Varadhachary, Gauri R.
    Javle, Milind
    Shroff, Rachna T.
    Fogelman, David
    Overman, Michael
    Crane, Christopher
    Koay, Eugene H.
    Minsky, Bruce D.
    Das, Prajnan
    Evans, Douglas B.
    Lee, Jeffrey E.
    GASTROENTEROLOGY, 2016, 150 (04) : S1180 - S1180
  • [25] Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
    Qian, Zhi Rong
    Rubinson, Douglas A.
    Nowak, Jonathan A.
    Morales-Oyarvide, Vicente
    Dunne, Richard F.
    Kozak, Margaret M.
    Welch, Marisa W.
    Brais, Lauren K.
    Da Silva, Annacarolina
    Li, Tingting
    Li, Wanwan
    Masuda, Atsuhiro
    Yang, Juhong
    Shi, Yan
    Gu, Mancang
    Masugi, Yohei
    Bui, Justin
    Zellers, Caitlin L.
    Yuan, Chen
    Babic, Ana
    Khalaf, Natalia
    Aguirre, Andrew
    Ng, Kimmie
    Miksad, Rebecca A.
    Bullock, Andrea J.
    Chang, Daniel T.
    Tseng, Jennifer F.
    Clancy, Thomas E.
    Linehan, David C.
    Findeis-Hosey, Jennifer J.
    Doyle, Leona A.
    Thorner, Aaron R.
    Ducar, Matthew
    Wollison, Bruce
    Laing, Angelica
    Hahn, William C.
    Meyerson, Matthew
    Fuchs, Charles S.
    Ogino, Shuji
    Hornick, Jason L.
    Hezel, Aram F.
    Koong, Albert C.
    Wolpin, Brian M.
    JAMA ONCOLOGY, 2018, 4 (03)
  • [26] The value of PET/CT radiomics for predicting survival outcomes in patients with pancreatic ductal adenocarcinoma
    Kang, Yeon-koo
    Ha, Seunggyun
    Jeong, Ji Bong
    Oh, So Won
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [27] Pancreatic Ductal Adenocarcinoma
    Erickson, Lori A.
    MAYO CLINIC PROCEEDINGS, 2017, 92 (09) : 1461 - 1462
  • [28] Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
    Yu, Kenneth H.
    Hendifar, Andrew E.
    Alese, Olatunji B.
    Draper, Amber
    Abdelrahim, Maen
    Burns, Ethan
    Khan, Gazala
    Cockrum, Paul
    Bhak, Rachel H.
    Nguyen, Catherine
    DerSarkissian, Maral
    Duh, Mei Sheng
    Bahary, Nathan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [29] DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma
    Chang, Amy E.
    Radke, Marc R.
    Zhen, David B.
    Baker, Kelsey K.
    Coveler, Andrew L.
    Wong, Kit Man
    Pillarisetty, Venu G.
    Reddi, Deepti
    Redman, Mary W.
    Swisher, Elizabeth
    Chiorean, Elena Gabriela
    PANCREAS, 2021, 50 (05) : E50 - E52
  • [30] Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma
    Timothy E. Newhook
    Jose M. Soliz
    Laura R. Prakash
    Shannon Hancher-Hodges
    Barbra Bryce Speer
    Jonathan A. Wilks
    Naruhiko Ikoma
    Michael P. Kim
    Jeffrey E. Lee
    Matthew H. G. Katz
    Ching-Wei D. Tzeng
    Annals of Surgical Oncology, 2021, 28 : 1563 - 1569